EUSA buys rights to Innocoll products

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on developing and marketing drug products for oncology, pain control and critical care, has acquired rights to several products from Canadian drugmaker Innocoll Pharmaceuticals.

Products purchased under the agreement include the antibiotic surgical implant Collatramp G and the post-surgical pain control implant CollaRx bupivacaine, for all markets outside the USA. Under the terms of the deal, Innocoll will continue to manufacture and supply both products to EUSA in return for an upfront fee and developmental, regulatory and sales performance-based milestone payments. EUSA has also agreed to make an equity investment in the Canadian firm's parent company. Financial details of the accord were not provided.

The Anglo-US firm has also purchased Innocoll's pan-European sales and marketing infrastructure, as well as its established global distribution network, which operates in 25 countries worldwide.